Shield to develop new sales channels for Afecta
This article was originally published in Clinica
Shield Diagnostics says that it is in advanced discussion with a number of companies concerning the development of Shield's Afecta Activated Factor XII (AFT) cardiac diagnostic, with the intention of obtaining distribution through two more companies. Shield, which is already in partnership with Abbott Laboratories, is talking to companies that would run Afecta on point-of-care devices as well as those which would add it to a menu of tests on a laboratory analyser.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.